Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 52187K200 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
Winklevoss Capital Fund, LLC
13D/A
|
19.9% |
8/19/2026
Event 8/17/2026
|
||
| Winklevoss Capital Fund, LLC | 19.9% | |||
| Winklevoss Treasury Investments, LLC | 19.9% | |||
| Winklevoss Capital Management, LLC | 19.9% | |||
| Tyler Howard Winklevoss | 19.9% | |||
| Cameron Howard Winklevoss | 19.9% | |||
| Severns Sean Michael 13G | 10.6% |
11/18/2025
Event 11/12/2025
|
||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (4) | ||||
| BeiGene, Ltd. 13D/A | 0% |
10/31/2024
Event 10/31/2024
|
||
|
Balyasny Asset Management L.P.
13G/A
|
0% |
2/14/2025
Event 12/31/2024
|
||
| Balyasny Asset Management L.P. | 0% | |||
| Bam GP LLC | 0% | |||
| Balyasny Asset Management Holdings LP | 0% | |||
| Dames GP LLC | 0% | |||
| Dmitry Balyasny | 0% | |||
| Gilead Sciences, Inc. 13G/A | 0% |
2/12/2026
Event 12/31/2025
|
||
|
Samsara BioCapital, L.P.
13G/A
|
0% |
8/14/2025
Event 6/30/2025
|
||
| Samsara BioCapital, L.P. | 0% | |||
| Samsara BioCapital GP, LLC | 0% | |||
| Srinivas Akkaraju | 0% | |||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 3 | 163 k | $543 k |
| 2026 Q2 | 55 | 14.9 M | $9.13 M |
| 2026 Q1 | 47 | 7.32 M | $5.94 M |
| 2025 Q4 | 44 | 8.67 M | $10.1 M |
| 2025 Q3 | 37 | 12.7 M | $5.76 M |
| 2025 Q2 | 47 | 13.8 M | $4.08 M |
| 2025 Q1 | 49 | 16.7 M | $5.09 M |
| 2024 Q4 | 61 | 19.2 M | $55.3 M |
| 2024 Q3 | 53 | 14.8 M | $38.1 M |
| 2024 Q2 | 51 | 14.7 M | $28.9 M |
| 2024 Q1 | 50 | 8.47 M | $22.5 M |
| 2023 Q4 | 51 | 6.87 M | $28.5 M |
| 2023 Q3 | 46 | 7.74 M | $10.6 M |
| 2023 Q2 | 41 | 7.71 M | $24.1 M |